Durvalumab vs Gefitinib

## Durvalumab vs Gefitinib: Overview

This comparison examines the pharmacological differences between **Durvalumab** and **Gefitinib**.

## Mechanism of Action

**Durvalumab**: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

**Gefitinib**: Selective reversible inhibitor of EGFR tyrosine kinase.

## Pharmacokinetics

**Half-life**: Durvalumab — 17 days; Gefitinib — 48 hours.

## Chemical Properties

**Molecular Formula**: Durvalumab — N/A; Gefitinib — C22H24ClFN4O3.

**Molecular Weight**: Durvalumab — N/A; Gefitinib — 446.9000 g/mol.

**Type**: Durvalumab — Antibody; Gefitinib — Small molecule.